title: [Pathogenic bacteria in cystic fibrosis].
abstract: Since the CF gene identification in 1989 and despite the improvement of our knowledge in the physiopathology of the disease, bronchopulmonary infection determines the vital prognosis. Following Staphylococcus aureus infection, patients are colonized or colonized by Pseudomonas aeruginosa, greatly involved in the pulmonary deterioration. Other bacteria may be involved Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes sp. Intensive antibiotic treatment of primocolonisation helps to prevent or delay chronic colonisation. Chronic colonization needs a rational long term antibiotic strategy to prevent the occurrence of multiresistant germs; antibiotic cures are performed every 3 or 4 months before pulmonary exacerbation symptoms.
authors.affiliation: Service de microbiologie, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Mariani-Kurkdjian
authors.forename: E
authors.initials: E
authors.lastname: Bingen
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019121:Burkholderia Infections / Q000150:complications* / Q000188:drug therapy; D003550:Cystic Fibrosis / Q000382:microbiology* / Q000473:pathology; D024881:Drug Resistance, Bacterial; D016905:Gram-Negative Bacterial Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D011379:Prognosis; D011552:Pseudomonas Infections / Q000150:complications* / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity; D013203:Staphylococcal Infections / Q000150:complications* / Q000188:drug therapy; D020588:Stenotrophomonas / Q000472:pathogenicity*
chemical_list: D000900:Anti-Bacterial Agents